-
Something wrong with this record ?
A novel class of ZNF384 aberrations in acute leukemia
M. Zaliova, L. Winkowska, J. Stuchly, K. Fiser, P. Triska, M. Zwyrtkova, O. Hrusak, J. Starkova, L. Sramkova, J. Stary, J. Trka, J. Zuna
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2016
PubMed Central
from 2016
Europe PubMed Central
from 2016
ROAD: Directory of Open Access Scholarly Resources
from 2016
- MeSH
- Leukemia, Myeloid, Acute * genetics MeSH
- Immunophenotyping MeSH
- Humans MeSH
- Trans-Activators * genetics MeSH
- Transcription Factors MeSH
- Transcriptome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Fusion of the ZNF384 gene as the 3' partner to several different 5' partner genes occurs recurrently in B-cell precursor acute lymphoblastic and mixed phenotype B/myeloid leukemia. These canonical fusions (ZNF384r) contain the complete ZNF384 coding sequence and are associated with a specific gene expression signature. Cases with this signature, but without canonical ZNF384 fusions (ZNF384r-like cases), have been described previously. Although some have been shown to harbor ZNF362 fusions, the primary aberrations remain unknown in a major proportion. We studied 3 patients with the ZNF384r signature and unknown primary genetic background and identified a previously unknown class of genetic aberration affecting the last exon of ZNF384 and resulting in disruption of the C-terminal portion of the ZNF384 protein. Importantly, in 2 cases, the ZNF384 aberration, indel, was missed during the bioinformatic analysis but revealed by the manual, targeted reanalysis. Two cases with the novel aberrations had a mixed (B/myeloid) immunophenotype commonly associated with canonical ZNF384 fusions. In conclusion, we present leukemia cases with a novel class of ZNF384 aberrations that phenocopy leukemia with ZNF384r. Therefore, we show that part of the so-called ZNF384r-like cases represent the same genetic subtype as leukemia with canonical ZNF384 fusions.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003219
- 003
- CZ-PrNML
- 005
- 20220127150550.0
- 007
- ta
- 008
- 220113s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1182/bloodadvances.2021005318 $2 doi
- 035 __
- $a (PubMed)34529760
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Zaliova, Marketa $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u University Hospital Motol, Prague, Czech Republic
- 245 12
- $a A novel class of ZNF384 aberrations in acute leukemia / $c M. Zaliova, L. Winkowska, J. Stuchly, K. Fiser, P. Triska, M. Zwyrtkova, O. Hrusak, J. Starkova, L. Sramkova, J. Stary, J. Trka, J. Zuna
- 520 9_
- $a Fusion of the ZNF384 gene as the 3' partner to several different 5' partner genes occurs recurrently in B-cell precursor acute lymphoblastic and mixed phenotype B/myeloid leukemia. These canonical fusions (ZNF384r) contain the complete ZNF384 coding sequence and are associated with a specific gene expression signature. Cases with this signature, but without canonical ZNF384 fusions (ZNF384r-like cases), have been described previously. Although some have been shown to harbor ZNF362 fusions, the primary aberrations remain unknown in a major proportion. We studied 3 patients with the ZNF384r signature and unknown primary genetic background and identified a previously unknown class of genetic aberration affecting the last exon of ZNF384 and resulting in disruption of the C-terminal portion of the ZNF384 protein. Importantly, in 2 cases, the ZNF384 aberration, indel, was missed during the bioinformatic analysis but revealed by the manual, targeted reanalysis. Two cases with the novel aberrations had a mixed (B/myeloid) immunophenotype commonly associated with canonical ZNF384 fusions. In conclusion, we present leukemia cases with a novel class of ZNF384 aberrations that phenocopy leukemia with ZNF384r. Therefore, we show that part of the so-called ZNF384r-like cases represent the same genetic subtype as leukemia with canonical ZNF384 fusions.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunofenotypizace $7 D016130
- 650 12
- $a akutní myeloidní leukemie $x genetika $7 D015470
- 650 12
- $a trans-aktivátory $x genetika $7 D015534
- 650 _2
- $a transkripční faktory $7 D014157
- 650 _2
- $a transkriptom $7 D059467
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Winkowska, Lucie $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and
- 700 1_
- $a Stuchly, Jan $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and
- 700 1_
- $a Fiser, Karel $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and
- 700 1_
- $a Triska, Petr $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and
- 700 1_
- $a Zwyrtkova, Martina $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and
- 700 1_
- $a Hrusak, Ondrej $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Starkova, Julia $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Sramkova, Lucie $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and $u University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Stary, Jan $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and $u University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Trka, Jan $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Zuna, Jan $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u University Hospital Motol, Prague, Czech Republic
- 773 0_
- $w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 5, č. 21 (2021), s. 4393-4397
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34529760 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127150546 $b ABA008
- 999 __
- $a ok $b bmc $g 1750852 $s 1154368
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 5 $c 21 $d 4393-4397 $e 20211109 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
- LZP __
- $a Pubmed-20220113